NEW ZEALAND DATA SHEET
Noradrenaline (Biomed) 0.06 mg/mL, 0.1 mg/mL, 0.12 mg/mL, 0.16 mg/mL Solution for infusion

1 PRODUCT NAME
Noradrenaline 0.06 mg/mL Solution for infusion
Noradrenaline 0.1 mg/mL Solution for infusion
Noradrenaline 0.12 mg/mL Solution for infusion
Noradrenaline 0.16 mg/mL Solution for infusion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
All strengths indicated above relate to noradrenaline base, which is added as noradrenaline acid tartrate monohydrate.
All strengths contain sodium metabisulphite 0.2 mg/mL as an antioxidant and glucose 5% for tonicity.
For the full list of excipients, see Section 6.1.

3 PHARMACEUTICAL FORM
Noradrenaline is a sterile solution containing noradrenaline acid tartrate available in a range of ready to use strengths in flexible bags and syringes.
The pH range of the infusions is 3.0 – 4.6.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications
For the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion, and drug reactions).
As an adjunct in the treatment of cardiac arrest. To restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

4.2 Dose and method of administration
Noradrenaline is intended for use undiluted. It contains no antimicrobial preservatives. Discoloured solutions or those containing a precipitate should not be used.
Avoid contact with iron salts, alkalis, or oxidising agents.

Restoration of Blood Pressure in Acute Hypotensive States
Blood volume depletion should always be corrected as fully as possible before any vasopressor is administered. When, as an emergency measure, intra-aortic pressures must be maintained to prevent cerebral or coronary artery ischaemia, noradrenaline can be administered before and concurrently with blood volume replacement.
Administer by slow intravenous infusion, observing the response to an initial dose of 8 – 12 μg adrenaline base then adjust the flow rate to establish and maintain a low normal blood pressure (usually 80 – 100 mm Hg systolic) sufficient to maintain the circulation to vital organs. In previously hypertensive patients, it is recommended that the blood pressure should be raised no higher than 40 mm Hg below the pre-existing systolic blood pressure.
The average maintenance dose ranges from 2 – 4 μg adrenaline base per minute. Great individual variation occurs in the dose required to attain and maintain an adequate blood pressure. In all cases, dosage of noradrenaline should be titrated according to the response of the patient. Occasionally much larger or even enormous daily doses (as high as 68 mg noradrenaline base) may be necessary if the patient remains hypotensive, but occult blood
Noradrenaline (Biomed) 0.06 mg/mL, 0.1 mg/mL, 0.12 mg/mL, 0.16 mg/mL
Solution for infusion

volume depletion should always be suspected and corrected when present. Central venous pressure monitoring is usually helpful in detecting and treating this situation.

Duration of Therapy
The infusion should be continued until adequate blood pressure and tissue perfusion are maintained without therapy. Infusions of noradrenaline should be reduced gradually, avoiding abrupt withdrawal. In some of the reported cases of vascular collapse due to acute myocardial infarction, treatment was required for up to six days.

Adjunctive Treatment in Cardiac Arrest
Infusions of noradrenaline are usually administered intravenously during cardiac resuscitation to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means. [Noradrenaline’s powerful betaadrenergic stimulating action is also thought to increase the strength and effectiveness of systolic contractions once they occur.]

Average Dosage
To maintain systemic blood pressure during the management of cardiac arrest, noradrenaline is used in the same manner as described under Restoration of Blood Pressure in Acute Hypotensive States.

Paediatric population
The safety and efficacy of noradrenaline tartrate in children has not yet been established.

4.3 Contraindications
Noradrenaline should not be given to patients who are hypotensive from blood volume deficits except as an emergency measure to maintain coronary and cerebral artery perfusion until blood volume replacement therapy can be completed. If noradrenaline is continuously administered to maintain blood pressure in the absence of blood volume replacement, the following may occur: severe peripheral and visceral vasoconstriction, decreased renal perfusion and urine output, poor systemic blood flow despite "normal" blood pressure, tissue hypoxia, and lactate acidosis.

Noradrenaline should also not be given to patients with mesenteric or peripheral vascular thrombosis (because of the risk of increasing ischaemia and extending the area of infarction) unless, in the opinion of the attending physician, the administration of noradrenaline is necessary as a life-saving procedure.

Cyclopropane and halothane anaesthetics increase cardiac autonomic irritability and therefore seem to sensitise the myocardium to the action of intravenously administered adrenaline or noradrenaline. Hence, the use of noradrenaline during cyclopropane and halothane anaesthesia is generally considered contraindicated because of the risk of producing ventricular tachycardia or fibrillation.

The same type of cardiac arrhythmias may result from the use of noradrenaline in patients with profound hypoxia or hypercarbia.

4.4 Special warnings and precautions for use

Warnings
Noradrenaline should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe, prolonged hypertension may result.
Noradrenaline contains sodium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulphite sensitivity in the general population is unknown. Sulphite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

**Precautions**

**General**

Avoid Hypertension

Because of the potency of noradrenaline and because of varying response to pressor substances, the possibility always exists that dangerously high blood pressure may be produced with overdoses of this pressor agent. It is desirable, therefore, to record the blood pressure every two minutes from the time administration is started until the desired blood pressure is obtained, then every five minutes if administration is to be continued.

The rate of flow must be watched constantly, and the patient should never be left unattended while receiving noradrenaline. Headache may be a symptom of hypertension due to overdosage.

**Site of Infusion**

Whenever possible, infusions of noradrenaline should be given into a large vein, particularly an antecubital vein because, when administered into this vein, the risk of necrosis of the overlying skin from prolonged vasoconstriction is apparently very slight. Some authors have indicated that the femoral vein is also an acceptable route of administration. A catheter tie-in technique should be avoided, if possible, since the obstruction to blood flow around the tubing may cause stasis and increased local concentration of noradrenaline. Occlusive vascular diseases (for example, atherosclerosis, arteriosclerosis, diabetic endarteritis, Buerger's disease) are more likely to occur in the lower than in the upper extremity. Therefore, one should avoid the veins of the leg in elderly patients or in those suffering from such disorders. Gangrene has been reported in a lower extremity when infusions of noradrenaline were given in an ankle vein.

**Extravasation**

The infusion site should be checked frequently for free flow. Care should be taken to avoid extravasation of noradrenaline into the tissues, as local necrosis might ensue due to the vasoconstrictive action of the drug. Blanching along the course of the infused vein, sometimes without obvious extravasation, has been attributed to vasa vasorum constriction with increased permeability of the vein wall, permitting some leakage. This also may progress on rare occasions to superficial slough, particularly during infusion into leg veins in elderly patients or in those suffering from obliterative vascular disease. Hence, if blanching occurs, consideration should be given to the advisability of changing the infusion site at intervals to allow the effects of local vasoconstriction to subside.

**IMPORTANT -- Antidote for Extravasation Ischaemia**

To prevent sloughing and necrosis in areas in which extravasation has taken place, the area should be infiltrated as soon as possible with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of phentolamine, an adrenergic blocking agent. A syringe with a fine hypodermic needle should be used, with the solution being infiltrated liberally throughout the area, which is easily identified by its cold, hard, and pallid appearance. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperaemic changes if the area is infiltrated within 12 hours. Therefore, phentolamine should be given as soon as possible after the extravasation is noted.
Noradrenaline (Biomed) 0.06 mg/mL, 0.1 mg/mL, 0.12 mg/mL, 0.16 mg/mL
Solution for infusion

Paediatric Use
Safety and effectiveness in paediatric patients has not been established.

Geriatric Use
Clinical studies of noradrenaline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Although clinical experience has not identified differences in responses between the elderly and younger patients, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other therapy.

Noradrenaline should not be administered into the veins in the leg in elderly patients (see Section 4.4 - Precautions, Site of Infusion).

4.5 Interaction with other medicines and other forms of interaction
Cyclopropane and halothane anaesthetics increase cardiac autonomic irritability and therefore seem to sensitisate the myocardium to the action of intravenously administered adrenaline or noradrenaline. Hence, the use of noradrenaline during cyclopropane and halothane anaesthesia is generally considered contraindicated because of the risk of producing ventricular tachycardia or fibrillation. The same type of cardiac arrhythmias may result from the use of noradrenaline in patients with profound hypoxia or hypercarbia. Noradrenaline should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptiline or imipramine types, because severe, prolonged hypertension may result.

Noradrenaline should not be mixed with other medicines. Infusion solutions containing noradrenaline acid tartrate have been reported to be incompatible with alkalis and oxidising agents, barbiturates, chlorpheniramine, chlorothiazide, nitrofurantoin, phenytoin, sodium bicarbonate, sodium iodide, streptomycin, sulfadazine and sulfafurazole.

4.6 Fertility, pregnancy and lactation

Use in pregnancy
Category B3
Noradrenaline should be given to a pregnant woman only if clearly needed.

Animal studies indicate noradrenaline may impair placental perfusion and induce foetal bradycardia. It may also exert a contractile effect on the pregnant uterus and lead to foetal asphyxia in late pregnancy. However, the clinical significance of these changes to a human foetus is unknown. These possible risks to the foetus should therefore be weighed against the potential benefit to the mother.

Use in lactation
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when noradrenaline is administered to a nursing woman.

Fertility
Studies have not been performed.

4.7 Effects on ability to drive and use machines
No information held by the sponsor.
4.8 Undesirable effects

The following reactions can occur:

**Body As A Whole**
Ischaemic injury due to potent vasoconstrictor action and tissue hypoxia.

**Cardiovascular System**
Bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias.

**Nervous System**
Anxiety, transient headache.

**Respiratory System**
Respiratory difficulty.

**Skin and Appendages**
Extravasation necrosis at injection site.

Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. If plasma volumes are not corrected, hypotension may recur when noradrenaline is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g. decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischaemic injury. Gangrene of extremities has been rarely reported.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/)

4.9 Overdose

Overdosage with noradrenaline may result in headache, severe hypertension, reflex bradycardia, marked increase in peripheral resistance, and decreased cardiac output. In case of accidental overdosage, as evidenced by excessive blood pressure elevation, discontinue noradrenaline until the condition of the patient stabilises.

Overdoses or conventional doses in hypersensitive persons (e.g. hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

**Pharmacotherapeutic group:** Adrenergic and dopaminergic agent  
**ATC Code:** C01CA03

The chemical structure of noradrenaline acid tartrate is shown below:
Chemically, Noradrenaline Acid Tartrate, \((1R)-2\text{-Amino}-1\text{-}(3,4\text{-dihydroxyphenyl})\text{ethanol hydrogen (2R,3R)}\text{-2,3-dihydroxybutanedioate monohydrate,}

is a white or almost white crystalline powder. It is freely soluble in water, and slightly soluble in ethanol (96%).

Molecular Formula: \(\text{C}_{12}\text{H}_{17}\text{NO}_9\text{H}_2\text{O}\)

Molecular Weight: 337.3

CAS Registry No.: 69815-49-2

5.2 Pharmacokinetic properties

Absorption

Orally ingested noradrenaline is destroyed in the GI tract, and the drug is poorly absorbed after subcutaneous injection. After IV administration, a pressor response occurs rapidly. The drug has a short duration of action, and the pressor action stops within 1-2 minutes after the infusion is discontinued.

Distribution

Noradrenaline localises mainly in sympathetic nervous tissue. The drug crosses the placenta but not the blood-brain barrier.

Elimination

The pharmacologic actions of noradrenaline are terminated primarily by uptake and metabolism in sympathetic nerve endings. The drug is metabolised in the liver and other tissues by a combination of reactions involving the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). The major metabolites are normetanephrine and 3-methoxy-4-hydroxy mandelic acid (vanillylmandelic acid, VMA), both of which are inactive.

Other inactive metabolites include 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol. Noradrenaline metabolites are excreted in urine primarily as sulphate conjugates and, to a lesser extent, as glucuronide conjugates. Only small quantities of noradrenaline are excreted unchanged.

5.3 Preclinical safety data

Genotoxicity and carcinogenicity studies have not been performed.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

All strengths of Noradrenaline contain the following excipients:

Glucose, Sodium metabisulfite, Water for Injection

6.2 Incompatibilities

Noradrenaline should not be mixed with other medicines. Infusion solutions containing noradrenaline acid tartrate have been reported to be incompatible with alkalis and oxidising agents, barbiturates, chlorpheniramine, chlorothiazide, nitrofurantoin, phenytoin, sodium bicarbonate, sodium iodide, streptomycin, sulfadiazine and sulfafurazole.
**NEW ZEALAND DATA SHEET**

**Noradrenaline (Biomed) 0.06 mg/mL, 0.1 mg/mL, 0.12 mg/mL, 0.16 mg/mL**

**Solution for infusion**

### 6.3 Shelf life

The following products have a **12 months shelf life**:
- Noradrenaline 0.1 mg/mL
- Noradrenaline 0.12 mg/mL
- Noradrenaline 0.16 mg/mL
- Noradrenaline 0.06 mg/mL

### 6.4 Special precautions for storage

**Store at or below 25°C. Do not refrigerate or freeze.**
- Noradrenaline 0.1 mg/mL
- Noradrenaline 0.12 mg/mL
- Noradrenaline 0.16 mg/mL

**Store at 2°C to 8°C. Refrigerate. Do not freeze.**
- Noradrenaline 0.06 mg/mL

### 6.5 Nature and contents of container

Noradrenaline is available in 0.1 mg/mL and 0.12 mg/mL strengths in 100 mL IV bags in overwraps.

It is also available in 50 mL polypropylene syringes in the following strengths: 0.06 mg/mL and 0.16 mg/mL.

### 6.6 Special precautions for disposal

No special requirement.

### 7 MEDICINE SCHEDULE

Prescription medicine

### 8 SPONSOR

Biomed Limited
52 Carrington Road
Point Chevalier
Auckland

Phone: 0800 833 133

### 9 DATE OF FIRST APPROVAL

15 October 2020

### 10 DATE OF REVISION OF THE TEXT

August 2020

### SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>DATE</th>
<th>CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aug-20</td>
<td>Update shelf life and storage condition for Noradrenaline 0.06 mg/mL</td>
</tr>
<tr>
<td>22/11/19</td>
<td>Update to section 6.4 Do not refrigerate or freeze.</td>
</tr>
<tr>
<td>19/03/19</td>
<td>Update to SPC format; remove description of 0.08 mg/mL 50 mL syringe</td>
</tr>
<tr>
<td>09/07/18</td>
<td>Minor editorial to 4.2, 4.4, 4.6 and 6.5</td>
</tr>
<tr>
<td>14/05/18</td>
<td>6.3 - Revised shelf life for 0.06 mg/mL; Update to SPC format; Minor editorial</td>
</tr>
</tbody>
</table>